Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 26 March 2009, Vol. 113, No. 13, pp. 3119-3129.
Prepublished online as a Blood First Edition Paper on October 22, 2008; DOI 10.1182/blood-2008-06-164103.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Table and Figure
Right arrow All Versions of this Article:
blood-2008-06-164103v1
113/13/3119    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pende, D.
Right arrow Articles by Moretta, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pende, D.
Right arrow Articles by Moretta, A.
Related Collections
Right arrow Immunobiology
Right arrow Transplantation
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

TRANSPLANTATION

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity

Daniela Pende1, Stefania Marcenaro2, Michela Falco3, Stefania Martini1, Maria Ester Bernardo4, Daniela Montagna4, Elisa Romeo3, Céline Cognet5, Miryam Martinetti6, Rita Maccario7, Maria Cristina Mingari1,2, Eric Vivier5, Lorenzo Moretta2,3,8, Franco Locatelli4, and Alessandro Moretta2

1 Immunologia, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; 2 Dipartimento di Medicina Sperimentale, Università di Genova, Genoa, Italy; 3 Immunologia Clinica e Sperimentale, Istituto Giannina Gaslini, Genoa, Italy; 4 Oncoematologia Pediatrica, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo; Dipartimento di Scienze Pediatriche, Università di Pavia, Pavia, Italy; 5 Centre d'Immunologie de Marseille-Luminy, Université de la Méditeranée, Marseille, France; 6 Laboratorio di Tipizzazione Tissutale and 7 Laboratorio di Ricerca Trapianto di Midollo Osseo e Oncoematologia Pediatrica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; and 8 Centro di Eccellenza per la Ricerca Biomedica, Università di Genova, Genoa, Italy

We analyzed 21 children with leukemia receiving haploidentical hematopoietic stem cell transplantation (haplo-HSCT) from killer immunoglobulin (Ig)–like receptors (KIR) ligand-mismatched donors. We showed that, in most transplantation patients, variable proportions of donor-derived alloreactive natural killer (NK) cells displaying anti-leukemia activity were generated and maintained even late after transplantation. This was assessed through analysis of donor KIR genotype, as well as through phenotypic and functional analyses of NK cells, both at the polyclonal and clonal level. Donor-derived KIR2DL1+ NK cells isolated from the recipient displayed the expected capability of selectively killing C1/C1 target cells, including patient leukemia blasts. Differently, KIR2DL2/3+ NK cells displayed poor alloreactivity against leukemia cells carrying human leukocyte antigen (HLA) alleles belonging to C2 group. Unexpectedly, this was due to recognition of C2 by KIR2DL2/3, as revealed by receptor blocking experiments and by binding assays of soluble KIR to HLA-C transfectants. Remarkably, however, C2/C2 leukemia blasts were killed by KIR2DL2/3+ (or by NKG2A+) NK cells that coexpressed KIR2DS1. This could be explained by the ability of KIR2DS1 to directly recognize C2 on leukemia cells. A role of the KIR2DS2 activating receptor in leukemia cell lysis could not be demonstrated. Altogether, these results may have important clinical implications for the selection of optimal donors for haplo-HSCT.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
E. Marcenaro, C. Cantoni, S. Pesce, C. Prato, D. Pende, S. Agaugue, L. Moretta, and A. Moretta
Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction
Blood, November 5, 2009; 114(19): 4108 - 4116.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020